{"disease":{"id":"toxic-plasma-methotrexate-concentration-reduction","name":"Toxic plasma methotrexate concentration reduction","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"glucarpidase","indication_name":"Toxic plasma methotrexate concentration reduction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Voraxaze","generic_name":"GLUCARPIDASE","company_name":"Btg International Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Carboxypeptidase [EPC]","quality_score":60,"revenue":null,"mechanism":"Voraxaze works by breaking down the chemotherapy medication methotrexate into a less toxic form."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}